Patients with active acromegaly are insulin-resistant and glucose-intolerant, whereas children with growth hormone (GH) deficiency (GHD) are insulin-sensitive and may develop fasting hypoglycaemia. Surprisingly, however, hypopituitary adults with unsubstituted GHD tend to be insulin-resistant, which may worsen during GH substitution. During fasting, which may be considered the natural domain for the metabolic effects of GH, the induction of insulin resistance by GH is associated with enhanced lipid oxidation and protein conservation. In this particular context, insulin resistance appears to constitute a favourable metabolic adaptation. The problem is that GH substitution results in elevated circadian GH levels in non-fasting patients. The best way to address this challenge is to employ evening administration of GH and to tailor the dose. Insulin therapy may cause hypoglycaemia and GH substitution may cause hyperglycaemia. Such untoward effects should be minimized by carefully monitoring the individual patient.

Keywords:
Growth hormone, Growth hormone deficiency, Insulin resistance
1.
Houssay BA: The hypophysis and metabolism. N Engl J Med 1936;214:961–985.
2.
Luft R, Ikkos D, Gemzell C-A, Olivencrona H: Lancet 1968;1:721–722.
3.
Beshyah SA, Henderson A, Niththyanathan R, Sharp P, Richmond W, Johnston D: Metabolic abnormalities in growth hormone-deficient adults. II. Carbohydrate tolerance and lipid metabolism. Endocrinol Metab 1994;1:173–180.
4.
Hew FL, Koschman M, Christopher M, Rantzau M, Vaag A, Ward G, Beck-Niels H, Alford F: Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 1996;81:555–564.
5.
Rabinowitz D, Klassen GA, Zierler KL: Effects of human growth hormone on muscle and adipose tissue metabolism in the forearm of man. J Clin Invest 1965;44:51–61.
6.
Glick SM, Roth J, Yalow RS, Berson SA: Immunoassay of human growth hormone in plasma. Nature 1963;199:784–787.
7.
Hartman ML, Faria ACS, Vance ML, Johnson ML, Thorner MO, Veldhuis JD: Temporal structure of in vivo growth hormone secretory events in humans. Am J Physiol 1991;250:E101–E110.
8.
Møller N, Jørgensen JOL, Schmitz O, Møller J, Christiansen JS, Alberti KGMM: Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol 1990;258:E86–E91.
9.
Bak JF, Møller N, Schmitz O: Effects of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans. Am J Physiol 1991;260:E736–E742.
10.
Ørskov L, Schmitz O, Jørgensen JOL, Arnfred J, Abildgaard N, Christiansen JS: Influence of growth hormone on glucose-induced glucose uptake in healthy man as assessed by the hyperglycemic clamp technique. J Clin Endocrinol Metab 1989;68:276–282.
11.
Møller N, Schmitz O, Jørgensen JOL, Astrup J, Bak JF, Christensen SE, Alberti KGMM, Weeke J: Basal and insulin stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992;74:1012–1019.
12.
Sönksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabaaro JDN: Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 1967;27:1418–1430.
13.
Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ: Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003;149:521–527.
14.
Rose DR, Clemmons DR: Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002;12:418–424.
15.
Møller N, Møller J, Jørgensen JOL, Ovesen P, Schmitz O, Alberti KGMM, Christiansen JS: Impact of 2 weeks’ growth hormone treatment on basal and insulin stimulated substrate metabolism in humans. Clin Endocrinol 1993;39:577–581.
16.
Johansson J-O, Fowelin J, Landin K, Lager I, Bengtsson B-Å: Growth hormone-deficient adults are insulin resistant. Metabolism 1995;44:1126–1129.
17.
Vahl N, Jørgensen JOL, Jurik AG, Christiansen JS: Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. J Clin Endocrinol Metab 1996;81:2209–2215.
18.
Fowelin J, Attvall S, Lager I, Bengtsson B-Å: Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993;42:1443–1447.
19.
Jørgensen JOL, Møller J, Alberti KGMM, Schmitz O, Christiansen JS, Møller N: Marked effects of sustained low growth hormone (GH) levels on day-to-day fuel metabolism: studies in GH deficient patients and healthy untreated subjects. J Clin Endocrinol Metab 1993;77:1589–1596.
20.
O’Neal DN, Kalfas A, Dunning PL, Christopher MJ, Sawyer SD, Ward GM, Alford F: The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J Clin Endocrinol Metab 1994;79:975–983.
21.
Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J: The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995;80:153–159.
22.
Christopher M, Hew FL, Oakley M, Rantzau C, Alford F: Defects of insulin action and skeletal muscle metabolism in growth hormone-deficient (GHD) adults persist following 24 months’ recombinant growth hormone therapy. J Clin Endocrinol Metab 1998;83:1668–1681.
23.
Beshyah SA, Henderson A, Niththyanathan R, Skinner E, Anyaoku V, Richmond W, Sharp P, Johnston D: The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995;80:356–363.
24.
Rosenfalck AM, Maghsoudi S, Fisker S, Jørgensen JO, Christiansen JS, Hilsted J, Volund AA, Madsbad S: The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 2000;85:4173–4181.
25.
Hwu C-M, Kwok CF, Lai T-Y, Shih KC, Lee TS, Hsiao LC, Lee SH, Fang VS, Ho LT: Growth hormone replacement reduces total body fat and normalises insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997;82:3285–3292.
26.
Jørgensen JOL, Vahl N, Nyholm B, Juul A, Müller J, Møller N, Schmitz O, Skakkebaæk NE, Christiansen JS: Substrate metabolism and insulin sensitivity following long-term growth hormone (GH) replacement therapy in GH-deficient adults. Endocrinol Metab 1996;3:281–286.
27.
Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH, Russell-Jones D: The effect of 10 years of recombinant growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999;84:2596–2602.
28.
Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785–789.
29.
Nielsen S, Møller N, Christiansen JS, Jørgensen JO: Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 2001;50:2301–2308.
30.
Møller N, Butler PC, Antsiferov MA, Alberti KGMM: Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia 1989;32:105–110.
31.
Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171–176.
32.
Nørrelund H, Djurhuus C, Jørgensen JO, Nielsen S, Nair KS, Schmitz O, Christiansen JS, Møller N: Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients. Am J Physiol Endocrinol Metab 2003;285:E737–E743.
33.
Rabinowitz D, Zierler KL: A metabolic regulating device based on the actions of human growth hormone and of insulin singly and together on the human forearm. Nature 1963;199:913–915.
34.
Jørgensen JOL: Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr Rev 1991;12:189–207.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.